Abstract
The first successful therapeutic iron chelator was desferrioxamine which was introduced in the late 1960’s by Ciba (now Novartis). Desferrioxamine has been an extremely successful compound having received the MMW “Pharmaceutical of the year” award for 1991. It is a life saving and a life – prolonging drug which improves the quality of life. However it is not orally active and its administration is both uncomfortable and expensive.
Over the past twenty years there has been a growing interest in the orally active iron chelators, deferiprone and exjade, both having been extensively studied. The ability of these compounds to mobilize iron from the heart and endocrine tissue has presented the clinician with some advantages over desferrioxamine. Other orally active iron chelators are currently under development and one, FBS0701 is in clinical trial.
The critical features necessary for the design of therapeutically useful iron chelators is presented in this review, together with recent studies devoted to the design of such chelators. This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes.
Keywords: Iron chelators, hydroxamates, desferrioxamine, hydroxypyridinones, deferiprone, exjade
Current Medicinal Chemistry
Title:Chelating Agents for the Treatment of Systemic Iron Overload
Volume: 19 Issue: 17
Author(s): Y. Ma, T. Zhou, X. Kong and R. C. Hider
Affiliation:
Keywords: Iron chelators, hydroxamates, desferrioxamine, hydroxypyridinones, deferiprone, exjade
Abstract: The first successful therapeutic iron chelator was desferrioxamine which was introduced in the late 1960’s by Ciba (now Novartis). Desferrioxamine has been an extremely successful compound having received the MMW “Pharmaceutical of the year” award for 1991. It is a life saving and a life – prolonging drug which improves the quality of life. However it is not orally active and its administration is both uncomfortable and expensive.
Over the past twenty years there has been a growing interest in the orally active iron chelators, deferiprone and exjade, both having been extensively studied. The ability of these compounds to mobilize iron from the heart and endocrine tissue has presented the clinician with some advantages over desferrioxamine. Other orally active iron chelators are currently under development and one, FBS0701 is in clinical trial.
The critical features necessary for the design of therapeutically useful iron chelators is presented in this review, together with recent studies devoted to the design of such chelators. This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes.
Export Options
About this article
Cite this article as:
Ma Y., Zhou T., Kong X. and C. Hider R., Chelating Agents for the Treatment of Systemic Iron Overload, Current Medicinal Chemistry 2012; 19 (17) . https://dx.doi.org/10.2174/092986712800609724
DOI https://dx.doi.org/10.2174/092986712800609724 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Current Pharmaceutical Design The Role of miRNAs in Metabolic Diseases
Current Medicinal Chemistry A Comprehensive Review of Essential Aspects of Molecular Pathophysiological Mechanisms with Emerging Interventions for Sarcopenia in Older People
Current Molecular Pharmacology Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Post-cardiac Arrest Syndrome in Children
Current Pediatric Reviews The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure
Current Medicinal Chemistry Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Editorial (Thematic Issue: Calcium in Heart Disease: The Ubiquitous Ion)
Medicinal Chemistry Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads
Current Medical Imaging Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Association between Apo B Levels in Mothers and in their Pre-school Age Offspring
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Effects of Immunosenescence on the Lower Expression of Surface Molecules in Neutrophils and Lymphocytes
Current Aging Science Oxidative stress and myocarditis
Current Pharmaceutical Design Heart Infection Prognosis Analysis by Two-dimensional Spot Tracking Imaging
Current Medical Imaging